Fusataka Koide

Director of Virology

P: 301-228-2188

Contact
Close

Contact Fusataka Koide

Fusataka Koide joined Southern Research’s Infectious Disease program in 2007. He brings 18 years of experience in research and program leadership to the project team. Koide also serves as liaison to various Japanese pharmaceutical companies as Japan business development manager.*

Koide specializes in the use of NHPs for evaluation of novel vaccines and therapeutics for emerging infectious diseases including dengue, Zika, and yellow fever. He has over 10 years of direct experience managing NHP studies as a PI and study director. His work has included analysis of humoral and cell-mediated immune responses in vaccinated and/or infected animals with an emphasis on attempting to identify correlates of immune protection against disease.

Throughout his tenure at SR, Koide has directed multiple PHS-funded projects under ABSL 2/3 environment; led studies including efficacy evaluation of anti-orthopoxvirus immunotherapeutic, immunogenicity and efficacy of combination VEE Replicon Particles (VRP); and directed the immunogenicity and protective efficacy evaluation of live attenuated H7N7 and H7N9 vaccines. He is currently directing assay development and GLP-enabling assay validation clinical programs for flaviviruses.

In May of 2000, Koide joined Dr. Philip Livingston’s laboratory in the Department of Tumor Vaccinology at Memorial Sloan-Kettering Cancer Center to work on murine immunogenicity and toxicity studies of a newly developed cancer vaccines. He was also involved in more than 10 FDA Phase I and Phase II clinical trial projects. In addition, he was a project lead in the development of an animal model for a gene-gun and electroporation DNA vaccine delivery project. At Nabi Biopharmaceuticals, where he was involved in research and development of a pentavalent vaccine against Methicillin-resistant Staphylococcus aureus (MRSA), he acquired knowledge and expertise in mouse and rabbit efficacy models for infectious disease.

Additionally, Koide has led the dengue virus (DENV) in vivo model development in NHP, and his work was published during 2010 American Society for Microbiology Annual Meeting. He is currently directing multiple dengue and Zika vaccine pre-clinical and clinical programs for commercial and government clients. His most recent research interests focus on the animal model development for Zika virus infection in NHP. SR’s latest research findings on Zika virus were published in a various peer-reviewed journals.
Koide obtained his master’s in immunology and microbiology at the New York Medical College.

* SR is providing research support solutions to a growing Japan market through official distributor Three-S Japan.

Publications